ClinicalTrials.gg
RecruitingNCT07211347Updated Oct 7, 2025

Percutaneous Blockade of the Stellate Ganglion in Electrical Storm

A Phase 4 interventional study of Stellate Ganglion Block in Electrical Storm, Stellate Ganglion Block and Ventricular Arrhythmia, sponsored by University of Sao Paulo General Hospital. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by University of Sao Paulo General Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

There is no randomized clinical study in the literature that evaluated the efficacy and safety of the stellate ganglion infiltration procedure in patients with electrical storm. So far, case reports and retrospective studies suggest that such a strategy should be considered in cases refractory to initial therapy. In this scenario, the European and American guidelines for the treatment of ventricular arrhythmias recommend autonomic modulation in this setting, but only with a level of recommendation IIb (1,2). This project aims to evaluate the effect of stellate ganglion infiltration in patients with electric storm refractory to initial clinical measures. It is a randomized clinical trial where patients will receive treatment with a lidocaine and bupivacaine anesthetic solution or no intervention. The effect of the intervention will be considered positive when there is a reduction of arrhythmic events of at least 50% in the 12 hours immediately after.

Read the detailed description

The study aims to evaluate the reduction of arrhythmic events following stellate ganglion blockade in patients with electrical storm refractory to initial clinical measures.

Hypothesis Stellate ganglion infiltration is an effective neuromodulation strategy for controlling arrhythmic events in patients with electrical storm awaiting definitive therapy.

Methodology This is a single-center randomized study investigating the efficacy of stellate ganglion blockade in patients with electrical storm refractory to initial clinical measures.

Participant Selection and Sample Size Participants will include patients admitted to the Emergency Unit or any Intensive Care Unit with a diagnosis of refractory electrical storm. Based on the STAR study, which reported a median of 6 arrhythmic events before SGB (IQR: 3 to 15.8), and aiming for at least a 50% reduction in arrhythmias in the active group post-procedure (with no expected change in the placebo group), a sample size of 32 patients per group was calculated (alpha = 0.05, power = 80%, two-tailed test).

Definitions Electrical storm (ES) is defined as three or more episodes of ventricular arrhythmias (including appropriate ICD therapies), separated by at least 5 minutes, within 24 hours. Refractory ES is defined as recurrent arrhythmias despite antiarrhythmic drug administration. Patients requiring discontinuation of antiarrhythmics due to adverse events will also be eligible for SGB. An arrhythmic event is defined as an episode of sustained VT or VF (>30 seconds or unstable), treated or not with antitachycardia pacing (ATP), electrical therapy, ICD shock, or external defibrillation. Pre-specified complications include: simple hematoma, hematoma requiring intervention, symptoms due to anesthetic absorption, brachial plexus injury, simple vascular injury, and vascular injury requiring intervention.

Randomization Randomization will be performed by a medical professional not involved in the infiltration procedure and blinded to data analysis, using the "Randomizer for Clinical Trial" software.

02

Conditions studied

  • Electrical Storm
  • Stellate Ganglion Block
  • Ventricular Arrhythmia

Browse trials for

Keywords

  • Ventricular Arrhythmia
  • Electrical Storm
  • Stellate ganglion block
03

In context

Ganglion Cysts

42 studies on the registry are indexed under Ganglion Cysts; 7 are open to participants now.

This study's planned enrollment of 64 is close to the median of 62 across 31 interventional studies indexed under Ganglion Cysts.

Browse Ganglion Cysts studies →

Lead sponsor

University of Sao Paulo General Hospital is the lead sponsor of 612 studies on the registry; 99 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years old with structural heart disease and a diagnosis of electrical storm, or those who require discontinuation of antiarrhythmics due to adverse events or to standard therapy.

Exclusion criteria

Exclusion Criteria:

  • Patients under 18
  • History of heart transplant or prior cardiac denervation surgery
  • Anatomical for the procedure (prior neck surgery, burns, large scars, or thyroid goiter).
  • Genetically related polymorphic VT
  • End-stage renal disease on dialysis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Active comparator
    Stellate Ganglion Block

    Procedure: Stellate Ganglion Block

  • No intervention
    Standard Treatment

Interventions

  • ProcedureStellate Ganglion Block

    There is no randomized clinical study in the literature that evaluated the efficacy and safety of the stellate ganglion infiltration procedure in patients with electrical storm.

06

What researchers measure

Primary outcomes

  1. Reduction in arrhythmic events

    A ≥50% reduction in arrhythmic events (VT/VF)

    Time frame: 12 hours immediately after the blockade compared to the 12 hours immediately before

Secondary outcomes

  1. ICD therapies

    Reduction in the number of ATPs/ICD shocks

    Time frame: 12 hours immediately after stellate ganglion block (SGB) compared to the 12 hours immediately before

  2. Urgent ablation and other invasive therapies

    urgent ablation and other invasive therapies (e.g., intra-aortic balloon pump placement or intubation for deep sedation)

    Time frame: 72 hours after the blockade

07

Study locations

1 of 1 sites recruiting
  • Clinical Research Center of the Heart Institute - University of São Paulo
    São Paulo, São Paulo 05409011, Brazil
    Recruiting
    • Alberto P Ferraz, MD · Contactalbertopferraz@gmail.com · 11981043839
    • · Contactalbertopferraz@gmail.com
    • Maurício I Scanavacca, MD, PhD · Principal investigator
    • Alberto P Ferraz, MD · Sub investigator
    • Rodrigo M Kulchetscki, MD · Sub investigator
08

References and documents

Publications

  • Savastano S, Baldi E, Compagnoni S, Rordorf R, Sanzo A, Gentile FR, Dusi V, Frea S, Gravinese C, Cauti FM, Iannopollo G, De Sensi F, Gandolfi E, Frigerio L, Crea P, Zagari D, Casula M, Sangiorgi G, Persampieri S, Dell'Era G, Patti G, Colombo C, Mugnai G, Notaristefano F, Barengo A, Falcetti R, Perego GB, D'Angelo G, Tanese N, Currao A, Sgromo V, De Ferrari GM; STAR study group. Electrical storm treatment by percutaneous stellate ganglion block: the STAR study. Eur Heart J. 2024 Mar 7;45(10):823-833. doi: 10.1093/eurheartj/ehae021. PubMed 38289867 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Oct 7, 2025
StartActual
Jun 6, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07211347
Responsible party
Sponsor
First posted
Oct 7, 2025
Start date
Jun 6, 2025
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 7, 2025

Study contacts

Alberto P Ferraz, MD
Contact
albertopferraz@gmail.com
+5511981043839
Maurício I Scanavacca, MD, PhD
principal investigator · Instituto do Coração - HC/FMUSP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion